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Abstract
A novel complex, [Cu(acetylethTSC)Cl]Cl•0.25C2H5OH 1 (where acetylethTSC = (E)-N-ethyl-2-
[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide), was shown to have anti-proliferative 
activity against various colon and aggressive breast cancer cell lines. In vitro studies showed that 
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complex 1 acted as a poison inhibitor of human topoisomerase IIα, which may account for the 
observed anti-cancer effects.
Graphical abstract
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cyclic voltammetry
The limited efficacy of current treatments for advanced breast and colon cancers has served 
as an impetus for a concerted effort to identify chemo-preventive agents for treatment. This 
process has often involved the use of metal complexes.[1] Cisplatin is widely used for the 
treatment of many cancers[2] despite its high toxicity, undesirable side effects, and problems 
with drug resistance in primary and metastatic cancers.[3] These limitations have spurred a 
growing interest in novel non-platinum metal complexes that can show anti-cancer 
properties.[4] Ruthenium-containing complexes have been reported to possess several 
favourable properties suited to rational anti-cancer drug design,[5] and ruthenium-containing 
complexes of various types are actively studied as metallodrugs, as they are believed to have 
low toxicity and good selectivity for tumours.[6] Recently, we reported the effect of 
ruthenium(II) complexes with new chelating thiosemicarbazones on growth inhibition of 
MCF-7 and MDA-MB-231 (breast adenocarcinoma) as well as HCT 116 and HT-29 
(colorectal carcinoma) cell lines.[7] Thiosemicarbazones and their metal complexes are used 
in many applications, ranging from pharmacology to nuclear medicine.[8] We have 
expanded our efforts by searching for non-ruthenium systems, for example; the use of 
gallium(III)- and vanadium(IV)-containing complexes with thiosemicarbazones as ligands, 
as potential anti-cancer agents.[9, 10] Copper(II) thiosemicarbazone complexes in particular 
have been the focus of investigation as metallodrugs for various medical applications for a 
long period of time. These applications include use as anti-cancer agents.[11, 12]
A number of copper(II) complexes have been shown to have anti-tumour activity, and their 
mechanism of action is believed to be inhibition of human topoisomerase IIα.[13, 14] 
Topoisomerases are attractive targets for anti-cancer drugs. They are ubiquitous enzymes 
that are required for untangling DNA and restoring the native DNA topology after processes 
such as replication, transcription, and other events that distort the DNA topology.[15] 
Topoisomerases are essential for cell viability. These enzymes employ an active site tyrosine 
residue to attack the phosphodiester backbone of the DNA, causing the strand to break. The 
enzyme then passes the other strand through the break, religates it, and releases the now 
untangled DNA.[15, 16] An important feature of this mechanism is the ensuing covalent 
intermediate where the enzyme is covalently linked to the cleaved DNA. While this 
intermediate persists, the cell is in danger, as accumulation of DNA breaks can cause DNA 
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damage response in cells, and even apoptosis.[16] Topoisomerase poison inhibitors that can 
stabilize this covalent intermediate can be extremely effective anti-bacterial or anti-cancer 
drugs.[17]
Human topoisomerase IIα (hTop2α) is highly expressed in many cancer cells, which makes 
it an attractive target for anti-cancer drugs.[18] There have been many reports of metal-
based complexes inhibiting human topoisomerase IIα, including some platinum complexes 
and other copper complexes as well, as mentioned above.[13, 14, 19, 20] However, many of 
these previous findings with copper(II) complexes have not shown poison inhibition of 
hTop2α, but rather catalytic inhibition, or have not determined the mechanism of 
topoisomerase inhibition at all. The identification of a novel poison inhibitor is significant, 
because topoisomerase poisons are highly effective anti-cancer agents. Poison inhibitors are 
highly effective because trapping of the covalent intermediates formed by only a small 
percentage of the target topoisomerases on cleaved chromosomal DNA by the drugs is 
sufficient to initiate cancer cell death. In contrast, near complete inhibition of the catalytic 
activity of the target enzyme may be needed for a catalytic inhibitor of an essential enzyme 
to be effective in cancer cell growth inhibition.[21]
Here, our research efforts have been extended to a novel copper(II) complex, which bears 
the thiosemicarbazone, E)-N-ethyl-2-[1-(thiazol-2-
yl)ethylidene]hydrazinecarbothioamide[10] (acetylethTSC). As such, we now report the 
characterization of a novel copper(II) complex, complex 1, which can act as an anti-tumour 
agent and as an hTop2α poison inhibitor. To our knowledge, this complex is the first 
copper(II)-based complex to show measurable quantitative increases in the linear DNA 
cleavage product from trapped topoisomerase complex, with specificity to hTop2α over the 
hTop1. The poisoning of hTop2α is likely to lead to cell death, and may contribute 
significantly to the anti-cancer mode of action.
Complex 1 was prepared by reacting the thiosemicarbazone, (E)-N-ethyl-2-[1-(thiazol-2-
yl)ethylidene]hydrazinecarbothioamide (acetylethTSC) in ethanol (Scheme 1). The complex 
was characterised by elemental analysis, HRMS, FTIR, UV-visible, and ESR 
spectroscopies. ICP-MS was also used to determine the percentage of Cu in the sample. The 
elemental analysis data for the percentage of H is not fully consistent with the calculated 
value; this could be due to the fact that the discrepancy is only in the percentage of H, and is 
more likely due to an error in the analysis process. Based on this discrepancy, it was 
necessary to show the HRMS data which showed an m/z value of 614.912544 (Figure S1) of 
which the proposed binuclear complex 2 was detected from a methanolic solution. In 
complex 2 (as a binuclear species), the acetylEtTSC ligand was found to coordinate as a 
thiolate anion while being detected in the positive mode while in the chamber of the mass 
spectrometer. This is due to the fact that thiosemicarbazones ligands can exist as thione–
thiol tautomers (although the proton lost to form the anion formally belongs to the 
hydrazinic -NH group).[11] Such thiosemicarbazones can undergo tautomerisation and 
subsequent deprotonation of the thiol form allowing for a mono-anionic ligand.[11]
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The complex was soluble in DMSO as revealed by its UV-visible spectrum in DMSO 
(Figure S2, ESI). It is really clear that there are differences between the UV-visible spectra 
of the ligand and the complex (Figure S2, ESI). The UV-visible spectrum of complex 1 
shows a d–d transition, which has a molar extinction coefficient value of 182 M−1 cm−1 at 
624 nm. Complex 1 also showed other bands at 324 and 425, with molar extinction values of 
1.7 × 104 and 1.6 × 104 M−1 cm−1, respectively. In DMSO, the “free” ligand has a 
wavelength of 340 nm, with a molar extinction coefficient value of 2.8 × 104 M−1 cm−1. 
Conductivity measurements of a 1.0 mM DMSO solution of complex 1, where Λm = 31.0 ± 
2.0 μS cm−1 proved the existence of complex 1 as a 1:1 electrolyte based on the use of 
conductivity measurements to ascertain types of electrolytes in various solvents as reported 
in a review as written by Geary.[22] Complex 1 as a 1:1 electrolyte accounts for the 
presence of a mononuclear cation in DMSO.
The infrared spectrum of complex 1 (Figure S3, ESI) shows a band in the ν(N-H) region 
which may be attributed to the hydrazinic nitrogen, thus suggesting that the ligands are 
coordinated as the thione form.[10] The ligand is reported to have stretching frequencies of 
3164, 3054, and 1059, as designated for ν(-N1H), ν(N2H), and ν(N2-N3), respectively.[10] 
On the other hand, complex 1 exhibited stretching frequencies of 3190, 2973, and 1166, as 
designated for ν(-N1H), ν(N2H), and ν(N2-N3), respectively. The presence of a medium 
stretching frequency for C=S at 813 cm−1 was determined for the “free” ligand,[10] but 
upon coordination, this stretching frequency is decreased to 787 cm−1 for the presence of 
C=S in the thione form of the coordinated thiosemicarbazone.[10] Also, the strong 
stretching frequency assigned to the ν(C=N) in the spectrum occurs at 1543 cm−1,[10] but is 
shifted to 1567 cm−1, thus implying that there is coordination of the azomethine (C=N) to 
the copper(II) metal centre.[23] The stretching frequency at 1296 (ν(C=S) + ν (C=N)) is 
shifted to 1228 cm−1 in the FTIR spectrum for complex 1.
The ESR spectra in a frozen solution of DMSO shows the presence of a paramagnetic Cu(II) 
metal centre, where g⏊, g∥, A⏊, and A∥ were determined to be 2.0525, 2.1888, 12 G, and 
168.9 G, respectively (Figure S4, ESI). The ESR spectrum of the complex indicates an axial 
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Chemical Formula: C16H22CICu2N8S4 
Exact Mass: 614.91 
+ 
symmetry. As g∥ > g⏊ > 2.002, it can be inferred that the complex possesses an 
approximately square-planar geometry. This trend is also consistent with a dx2−y2 ground 
state.[24, 25] Sakaguchi and Addison[25] have shown that the g∥/A∥ ratio can be used as a 
convenient empirical index of tetrahedral distortion in CuN4 units. This value ranges from 
ca. 105 to 135 cm for the square planar structure, and this quotient increases on the 
introduction of tetrahedral distortion to the chromophore. Furthermore, tetrahedral distortion 
of a square-planar chromophore is observed when any (N, O, S) donors reduce A∥ and 
increase g∥. Using that relationship and the g∥/A∥ ratio of 139 cm (where g∥/A∥ = 
(2.1888/0.01579) cm) results in complex 1 having a tetrahedral distortion from the square 
planar geometry, and this is reflected in the structure for complex 1 as shown in Scheme 1. 
Such is structure is also based on the fact that the ligand can be tridentate in nature.
Electrochemical studies were also carried out on the ligand and complex 1, where some 
interesting features were observed in each cyclic voltammogram (Figure S5, ESI) for the 
metal centre and the thiosemicarbazone ligand (both coordinated and “free”). Recently, 
electrochemical studies of thiosemicarbazones has shown the existence of an irreversible 
cathodic redox peak in the region −1.26 V to −1.67 V, corresponding to the reduction of the 
imine moiety of the thiosemicarbazone functional group.[26] Such a case was observed of 
the “free” ligand, where Epc = −1.62 V is believed to be due to the reduction of the imine 
moiety. The redox potential, Epa = +0.704 V, is believed to be arise from the oxidation of 
the “free” ligand to a highly reactive radical cation followed by the formation of a dimeric 
species containing a disulphide bond.[27] The reduction of the thione functional group of a 
thiosemicarbazone moiety, have previously been reported to produce an irreversible 
cathodic peak at −1.06 V.[28] Previously reported electrochemical studies on 
thiosemicarbazone ligands have also shown the existence of an irreversible cathodic peak at 
−1.06 V.[28] We believe that the redox couple of E½ = −0.668 V is due to the reduction of 
the thione functional group. The cyclic voltammogram for complex 1 shows redox couples 
that are ligand- and metal-based. The irreversible Epa = +0.539 V is believed to be arise 
from the oxidation of the coordinated ligand to a highly reactive radical cation; while the 
irreversible Epc = −1.52 V is believed to be due to the reduction of the imine moiety. On the 
other hand the redox couple (CuII/I) is reversible at E½ = −0.207 V.
Once characterized, the anti-proliferative activity of complex 1 was carried out against colon 
cancer cell lines (HTC-116, Caco-2, and HT-29), and also compared to the anti-proliferative 
activity against one non-cancerous colon cell line (CCD-18Co). Complex 1 and etoposide 
(as positive control) were evaluated for their cytotoxicity against HCT-116, Caco-2, and 
HT-29 by a colorimetric assay (MTS), as described by Lewis et al.[10] Table S1 (ESI) 
summarizes the data from this evaluation. The effects of the compounds on the viability of 
these cells were evaluated after continuous incubation (24, 48, and 72 hours). In all cases, it 
was found that complex 1 had better efficacy in inhibiting cell growth of the colorectal 
cancer cells when compared to etoposide as shown in Table S1. Complex 1, however, was 
found to be very toxic to the non-cancerous colon cell line (CCD-18Co) when compared to 
etoposide, with IC50 values after 72 hours of 0.83 ± 0.80 and 41.2 ± 2.3 μM, respectively.
Based on the results from the above study, where it was found that complex 1 was very 
aggressive in inhibiting cell growth of these colorectal cancer cell lines, we decided to carry 
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out an in vitro study on very aggressive breast cancer lines that are highly malignant and 
demonstrate increased rates of cell growth, migration and invasion. As such, to extend the 
potential anti-oncogenic of complex 1, we examined its ability to prevent breast cancer cell 
proliferation in a preliminary study. In this preliminary study, we demonstrated a significant 
decrease in cell proliferation in four (4) different aggressive breast cancer cell lines, viz., 
HCC 1500, HCC 70, HCC 1806, and HCC 1395. The results (Figures S6–S9, ESI) that were 
obtained when HCC1500 cells were treated with the complex 1 at the concentrations 
indicated in each figure (Figures S6–S9, ESI) before incubation for 24 and 48 hours. The 
rate of cell proliferation was determined using an MTT cell proliferation assay. Each value 
is presented as the mean of the SEM of three independent determinations. The columns in 
each graph are presented as relative values in comparison to serum-starved cells. Bars 
labelled with different letters are significantly different from one another (P < 0.05). The 
black horizontal line denotes the level at which the rate of cell proliferation has been 
decreased by 50% of the growth factor control (positive control, yellow bar). The results 
(Figures S6–S9, ESI) demonstrated that complex 1 is able to prevent growth factor-
stimulated cell proliferation at concentrations ranging from 1 μM to 20 μM in all the cell 
lines assayed. Complex 1 was tested for its ability to prevent cell growth after being exposed 
to the cells for 24 and 48 hours, respectively. The exposure to complex 1 for 48 hours did 
not result in dramatic decreases in cell growth, suggesting that a 24 hour exposure to this 
complex was significant enough to prevent breast cancer cell proliferation.
Specifically, 5 μM of complex 1 was sufficient to reduce cell proliferation by 50% in all the 
cell lines after 24 hours (note black horizontal line on each figure (Figures S6–S9, ESI)). 
Additionally, with a longer exposure to the complex (48 hours), the amount of complex 1 
needed to reduce 50% of cell proliferation was only 2 μM for the HCC 70, HCC 1500, and 
HCC 1806 cell lines, however it remained at 5 μM for the HCC 1395 cell lines. This is 
interesting, since the HCC 1395 cell line is the only cell line that is derived from a 
Caucasian-American female, while the other three cell lines are derived from African-
American females.
To understand the complex’s mechanism for exerting toxicity on the cancer cell lines, the 
effect of the complex on hTOP2α activity was evaluated, since many anticancer drugs are 
known to target this enzyme. The complex’s effects on htop2α were determined in vitro. A 
standard assay for detecting topoisomerase inhibition involves gel electrophoresis; the 
enzyme’s ability to relax supercoiled DNA is determined in the presence and absence of the 
compound of interest.[29] When complex 1 was incubated with hTop2α, it prevented the 
enzyme’s ability to relax DNA. It was shown to inhibit the relaxation activity of human 
topoisomerase IIα with an IC50 value of 12.5–25 μM (Figure 1). The ligand alone has no 
effect on the enzyme activity.
Complex 1, in addition to inhibiting the relaxation activity of hTop2α, also produced an 
increase in the linear DNA cleavage product. The presence of linear DNA product indicates 
that the complex can act as a poison inhibitor of human topoisomerase IIα. As mentioned 
earlier, poison inhibitors prevent DNA religation following cleavage by the topoisomerase 
enzyme. The DNA-enzyme covalent intermediate persists, and the DNA is trapped with a 
double stranded break.[17] Figure 2 shows the increase in cleavage product observed for 
Sandhaus et al. Page 6
Inorg Chem Commun. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
complex 1. Free copper in the form of the copper(II) salt, CuCl2•2H2O, did not result in any 
significant increase in topoisomerase cleavage product. Densitometry analysis of the bands 
shows a 3.6-fold increase in linear DNA product when compared to the DMSO lane 
(negative control) for complex 1 at 100 μM, and a 2.8-fold increase at 25 μM.
These results are significant, because a quantitative increase in linear DNA cleavage product 
was not observed for other copper(II)-containing complexes reported in previous studies, for 
example, 1-((5(or 6)-carboxy-1H-benzo[d]imidazol-2-yl)methyl)pyridinium copper(II) 
chloride hydrate,[13] copper(II) complexes with α-heterocyclic thiosemicarbazones as 
ligands,[14] and an R- and S-enantiomeric copper(II) complex derived from N,N-bis(1-
benzyl-2-ethoxyethane),[19] all of which showed either little or no poisoning effect. In our 
study, this novel effect is significant, since the accumulation of topoisomerase cleavage 
intermediates would be an important mode of action for anti-cancer activity. Additionally, 
“free” Cu(II) ions and the acetylethTSC ligand were not able to poison the topoisomerase on 
their own, but it is the complex that is formed from the copper(II) metal centre and the 
ligand that exerted the poisoning effect.
To determine specificity, complex 1 was tested against human topoisomerase I. It exhibited 
little to no effect on the enzyme relaxation activity, supporting the hypothesis that complex 1 
can act as a specific inhibitor of hTop2α. Its effect on the type I enzyme is shown in Figure 
3.
This copper(II) complex is the first of its kind to show measurable quantitative increases in 
the linear DNA cleavage product from hTop2α. The quantitative increase in linear DNA (as 
shown in Figure 2 is indicative of a poison mechanism of inhibition, as an hTop2α poison 
would cause an increase in permanent double-stranded breaks. This mechanism of action is 
particularly lethal, and may account for the anti-proliferative effects exerted on the various 
cancer cell lines studied in this work reported within. Only a few stabilized htop2α covalent 
complex trapped by complex 1 on chromosomal DNA may be sufficient to initiate the 
apoptosis pathway. At 12.5 μM complex 1, the linear DNA product formed by htop2α on 
plasmid DNA increased by 30% as determined by densitometry analysis. Cytotoxicity from 
complex 1 could be observed at submicromolar concentrations. The level of htop2α covalent 
complex that can be trapped by complex 1 on chromosomal DNA in tumour cells might be 
further enhanced by the involvement of htop2α in DNA replication complexes. It is also 
possible that there may be additional mode of actions involved in the anti-tumour activity of 
complex 1. The in vivo effect of complex 1 and similar copper complexes should be 
investigated further in future studies.
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Highlights (for review)
• A novel copper(II) complex with (E)-N-ethyl-2-[1-(thiazol-2-
yl)ethylidene]hydrazinecarbothioamide) was synthesized and characterized
• Anti-proliferative activity against various colon (in one case, an IC50 value of 
242 nM) and aggressive breast cancer cell lines
• In vitro studies showed that compound acted as a poison inhibitor of human 
topoisomerase IIα, which is unlike most copper(II) complexes
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Figure 1. 
The effect of inhibition of hTop2α relaxation activity by complex 1. Lane 1: negatively 
supercoiled pBAD/Thio plasmid DNA with no enzyme; Lane 2: DMSO as negative control; 
Lane 3: positive control mAMSA at 75 μM; Lanes 4–6: 100, 50, and 25 μM acetylethTSC; 
Lanes 7–10: 100, 50, 25, and 12.5 μM complex 1. N = nicked, FR= fully relaxed, PR = 
partially relaxed, and S = supercoiled.
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Figure 2. 
The effect of poisoning of hTop2α in the presence of complex 1. Lane 1: negatively 
supercoiled pBAD/Thio plasmid DNA with no enzyme; Lane 2: DMSO as negative control; 
Lane 3: positive control mAMSA at 25 μM; Lanes 4–6: 200, 100, and 50 μM CuCl2•2H2O; 
Lanes 7–9: 100, 50, and 25 μM acetylethTSC; Lanes 10–13: 100, 50, 25, and 12.5 μM 
complex 1. Electrophoresis buffer contained 0.5 μg ml−1 ethidium bromide. N = nicked, L = 
linear, and CC = covalently closed.
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Figure 3. 
The effect complex 1 on human topoisomerase I activity. Lane 1: negatively supercoiled 
pBAD/Thio plasmid DNA; Lane 2: DMSO as negative control; Lane 3: positive control 
camptothecin at 100 μM; Lanes 4–6: 100, 50, and 25 μM acetylethTSC; Lanes 7–10: 100, 
50, 25, and 12.5 μM complex 1. N = nicked, FR = fully relaxed, PR = partially relaxed, and 
S = supercoiled.
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Scheme 1. 
Synthesis of complex 1.
Sandhaus et al. Page 15
Inorg Chem Commun. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
. j 
HN 
HN~ S 
13 
:r: 
'=1 
EtOH, reflux 2 hours 
73% 
HN_j 
~ 4\ 
I] s N 
,, ' I 
Cu-----
S "N/ Cl 
\ I 
